a public good project by the
Synthesis
Company
of California

© 2026

David H. Kirn | doi.page

0 works0 citations0 h-index

David H. Kirn

Alameda Applied Sciences Corporation (United States)(US)Therapeutics Clinical Research(US)University of California, Berkeley(US)

Publications by Year

Research Areas

Virus-based gene therapy research, CAR-T cell therapy research, Cancer Research and Treatments, Viral Infectious Diseases and Gene Expression in Insects, RNA Interference and Gene Delivery

Most-Cited Works

→ An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells(1996)1,754 cited
→ A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer(2000)1,100 cited
→ ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents(1997)946 cited
→ An essential role for Rac in Ras transformation(1995)884 cited
→ Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer(2013)762 cited
→ An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy(2000)584 cited

→ Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans(2011)

542 cited

→ Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial(2008)518 cited

→ Replication-selective virotherapy for cancer: Biological principles, risk management and future directions(2001)502 cited

A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.(2003)